Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Istvan Vincze"'
Autor:
Javier Martinez, Istvan Vincze, Gwen Pollner, David Ghosh, Diane Wigotzki, Hyo-Keun Kim, Marc Scharfe, Regina Stabbert, Rolf Lutz, Thilo Paschke, Marco Esposito, James Murphy, Thomas Lindegaard, Panagiotis Vlachos, Ewald Roemer, Liam Simms, Andrew Manson, Anna Clarke, Jarl Freiesleben
Publikováno v:
Regulatory Toxicology and Pharmacology. 104:84-97
This paper is part of a series of 3 publications and describes the non-clinical and clinical assessment performed to fulfill the regulatory requirement per Art. 6 (2) of the EU Tobacco Products Directive 2014/40/EU; under which Member States shall re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ad260be8de59e3f80172bbff53aa0b
https://doi.org/10.1016/j.yrtph.2019.02.011
https://doi.org/10.1016/j.yrtph.2019.02.011
Autor:
Adrienne Fehér, István Vincze, James Rudge, Gyula Domján, Barna Vásárhelyi, Gellért Balázs Karvaly
Publikováno v:
Diagnostics, Vol 14, Iss 17, p 1939 (2024)
Our aim was to compare the performance of complementary clinical laboratory approaches to monitoring exposure to apixaban and rivaroxaban, the most prescribed direct-acting oral anticoagulants (DOAC’s): an automated commercial anti-Xa chromogenic a
Externí odkaz:
https://doaj.org/article/68ddb8fe47c24536bc8770c6dcb0af6f
Publikováno v:
Economic Modelling. 41:46-54
This article models industrial new orders across the European Union (EU) countries for various breakdowns. A common modelling framework exploits soft (business opinion surveys) as well as hard data (industrial turnover). The estimates show for about
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::579ca40f91b2b390593776b732dbc31c
https://doi.org/10.1016/j.econmod.2014.04.004
https://doi.org/10.1016/j.econmod.2014.04.004
Autor:
Gellért Balázs Karvaly, István Vincze, Michael Noel Neely, István Zátroch, Zsuzsanna Nagy, Ibolya Kocsis, Csaba Kopitkó
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 358 (2024)
Population pharmacokinetic (pop-PK) models constructed for model-informed precision dosing often have limited utility due to the low number of patients recruited. To augment such models, an approach is presented for generating fully artificial quasi-
Externí odkaz:
https://doaj.org/article/66c127ee5e374e399f14cccabc4dec79
Following the discontinuation of the official statistics on industrial new orders by Eurostat in mid-2012, this paper introduces the ECB indicator on euro area industrial new orders, which aims to fill the new statistical gaps for euro area total new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c4ca54e88a4baac9d69d13cf7f66677
http://www.ecb.europa.eu/pub/pdf/scpops/ecbocp149.pdf
http://www.ecb.europa.eu/pub/pdf/scpops/ecbocp149.pdf
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 239 (2023)
Orally administered, small-molecule anticancer drugs with tumor-specific cellular protein targets (OACD) have revolutionized oncological pharmacotherapy. Nevertheless, the differences in exposure to these drugs in the systemic circulation and extrava
Externí odkaz:
https://doaj.org/article/1da3c3902d214d33b2ace8c1b8cacccd
Autor:
Gellért Balázs Karvaly, István Karádi, István Vincze, Michael N. Neely, Eszter Trojnár, Zoltán Prohászka, Éva Imreh, Barna Vásárhelyi, András Zsáry
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract The inadequate adherence of patients whose hyperlipidemia is treated with atorvastatin (ATR) to medical instructions presents a serious health risk. Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonpa
Externí odkaz:
https://doaj.org/article/e3277a6d16c34a73b9a26ecfca0b40fd
Autor:
Gellért Balázs Karvaly, István Vincze, Alexandra Balogh, Zoltán Köllő, Csaba Bödör, Barna Vásárhelyi
Publikováno v:
Molecules, Vol 27, Iss 15, p 4766 (2022)
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precis
Externí odkaz:
https://doaj.org/article/8edf52f11d1b4781ad1e50d2ef73d53b
Autor:
Gellért Balázs Karvaly, Michael N Neely, Krisztián Kovács, István Vincze, Barna Vásárhelyi, Roger W Jelliffe
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229873 (2020)
BACKGROUND:The clinical value of therapeutic drug monitoring can be increased most significantly by integrating assay results into clinical pharmacokinetic models for optimal dosing. The correct weighting in the modeling process is 1/variance, theref
Externí odkaz:
https://doaj.org/article/7f4aaddd49b54733b0e768b176d7c5a7
Publikováno v:
Environmental Health Perspectives. 99:307
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41910abc36617eaffe7a2d845ba6df15
https://doi.org/10.2307/3431507
https://doi.org/10.2307/3431507